ArticleRenal failure2026
Polydatin alleviates adenine-induced nephropathy in mice.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdenine-induced nephropathy (AIN) serves as a classic experimental model for studying uric acid-related renal injury, characterized by tubular obstruction, inflammatory cell infiltration, tubular epithelial cell apoptosis, and progressive interstitial fibrosis, among others. These pathological changes are primarily driven by intrarenal deposition of adenine metabolites, and the model reliably recapitulates both hyperuricemia and impaired renal function. The aim of this study was to assess the renoprotective potential of polydatin (PD) in a murine model of AIN.
methodsFifty male mice (weight, 20 ± 2 g) obtained from The Institute of Cancer Research were randomly assigned into five groups (
resultsThe outcomes of the present study revealed that renal function and renal histopathology in mice were significantly abnormal in the AIN group. After treatment with PD, it was observed that these abnormal indices were significantly improved, and the structure and function of renal histopathology were significantly protected.
conclusionsPD exhibited a significant therapeutic effect in mice with AIN, which may play a role in protecting the kidneys by regulating various biological processes such as immune inflammation, apoptosis, and fibrosis, providing an important experimental basis and theoretical basis for the clinical use of PD in treating AIN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.